First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer
Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Somesh Chattopadhyay(United States Food and Drug Administration), Robert Justice(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Kathryn E. King, Nancy S. Scher, Colleen J. Thomas(United States Food and Drug Administration), Laurie Graham(United States Food and Drug Administration), Wendy C. Weinberg(United States Food and Drug Administration), Anne M. Pilaro(United States Food and Drug Administration), Kimberly Ringgold(United States Food and Drug Administration), Pengfei Song(Nanyang Technological University), Patricia Cortazar(Center for Drug Evaluation and Research), Bo Chi(Center for Biologics Evaluation and Research), Amy Tilley(Center for Drug Evaluation and Research), Barbara L. Rellahan(United States Food and Drug Administration), P. E. Hughes(Center for Drug Evaluation and Research), Qi Liu(Southwest University)
Cited by 120
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k